Equipping the American Joint Committee on Cancer Staging for Resectable Pancreatic Ductal Adenocarcinoma with Tumor Grade: A Novel Staging System

الملخص EN

Background.

The 8th American Joint Committee on Cancer (AJCC) staging system for pancreatic ductal adenocarcinoma (PDAC) outperforms its previous version in reproducibility but not in survival discrimination.

Tumor grade, an indicator of the aggressive biology of PDAC, has been suggested as a reliable prognostic factor.

This study aimed to construct a novel staging system with greater prognostication for resectable PDAC by incorporating tumor grade into the 8th AJCC system.

Methods.

A total of 9966 patients with resectable PDAC from the Surveillance Epidemiology and End Results (SEER) database were randomly separated into training and interval validation sets.

Another 324 patients from our center were included as an external validation set.

We proposed a novel staging system by sorting the substages yielded by a combination of T, N, and tumor grade based on their overall survival (OS) and grouping them into several stages.

Prognostic homogeneity and discrimination were determined using the likelihood ratio χ2 and the linear trend χ2 test, respectively.

Prognostic accuracies were evaluated by the area under the receiver operating characteristics curve (AUC).

Results.

Using the 8th AJCC system, the prognosis of patients within the same stage was quite heterogeneous among different substages.

The multivariate Cox model identified the tumor grade (hazard ratio 1.333, 95% confidence interval 1.250–1.423, p<0.001) was an independent prognostic factor of the OS.

In the training set, the AUC, homogeneity, and discriminatory ability were superior for the novel staging system than for the 8th AJCC system (0.642 vs.

0.615, 403.4 vs.

248.6, and 335.1 vs.

218.0, respectively).

Similar results were observed in the internal and external validation sets.

Conclusions.

The novel staging system incorporating tumor grade into the 8th AJCC system was associated with better prognostic accuracy, homogeneity, and discriminatory ability among resectable PDAC patients.

Moreover, the novel staging system also allowed possibly adjuvant chemotherapy decisions.